From: Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia
Diet (n = 14) | Diet-plus-statin (n = 14) | P value | |
---|---|---|---|
Antihypertensive agents (n (%)) | |||
Angiotensin II receptor blockers | 12 (86) | 10 (71) | 0.324 |
Angiotensin-converting enzyme inhibitors | 2 (14) | 0 (0) | 0.241 |
Calcium-channel blockers | 10 (71) | 8 (57) | 0.430 |
Diuretics | 4 (29) | 3 (21) | 0.500 |
β-blockers | 4 (29) | 3 (21) | 0.500 |
α-blockers | 1 (7) | 0 (0) | 0.500 |
Central sympatholytic agents | 0 (0) | 1 (7) | 0.500 |
Glucose-lowering agents (n (%)) | |||
Insulin and insulin analougues | 0 (0) | 0 (0) | - |
Sulfonylureas | 0 (0) | 2 (14) | 0.241 |
α-glucosidase inhibitors | 3 (21) | 1 (7) | 0.298 |
Biguanides | 1 (7) | 0 (0) | 0.500 |
Thiazolidinediones | 0 (0) | 1 (7) | 0.500 |
Lipid-lowering agents (n (%)) | 0 (0) | 0 (0) | - |
Antiplatelet agents (n (%)) | 2 (14) | 3 (21) | 0.500 |